Search for New Physics in B Rare Decays at LHCb

The LHCb experiment, bolstered up by the 10^12 b-hadrons to be produced yearly in its interaction region, is an excellent place to study rare B decays. Flavor-changing neutral currents are forbidden at tree level in the Standard Model. They proceed through loop diagrams and hence are indirectly sensitive to New Physics through the effect of new particles on observable quantities. In this paper, we present preparation studies of the three most promising B rare decay analyzes. These aim at the observation of the photon polarization in B_s to phi gamma, the measurement of the angular distribution of the B^0 to K* mu^+ mu^- decay, and the search for the yet unobserved B_s to mu^+ mu^- decay. The current analysis strategies and the expected sensitivities are presented.Comment: To be published in the proceedings of DPF-2009, Detroit, MI, July 2009, eConf C090726; one reference adde

Construction of the Inner Tracker and Sensitivity to the B°s -> [mu][mu] Decay at LHCb

LHCb is one of the four main experiments hosted at the Large Hadron Collider (LHC) at CERN. The LHC first started in September 2008 and, after a one-year hiccough, restarted in November 2009. In the course of three weeks, the HEP community witnessed the first LHC proton-proton collisions and a new record of the most energetic particle beam. The ease shown by the operators of the complex LHC machine augurs very well for the extended period of data-taking scheduled to start at the end of February 2010. LHCb is the LHC experiment primarily dedicated to the b realm, through the study of CP violation and rare decays. Its physics goals are ambitious: it aims at the indirect search of New Physics and at the precise measurements of CP violation parameters. The LHCb detector was designed as a single-arm forward spectrometer. The branching fraction of the yet-unobserved Bs0 → μ+ μ- decay is currently considered as one of the most stringent tests for the existence of physics beyond the Standard Model (SM) of particle physics. There exists indeed a large unexplored range between the current experimental upper limit and the SM prediction about this branching fraction, making a measurement incompatible with the SM possible. Furthermore, there exist predictions for this branching fraction in the frame of numerous theoretical models that aim at a more accurate description of matter than that offered by the Standard Model. Some of those predictions significantly differ from the SM one, opening the possibility of an indirect discovery of New Physics. In this thesis, I present the study of the sensitivity of the LHCb experiment to this branching fraction with Monte Carlo simulations. I show that LHCb will compete with the Tevatron for the exclusion limit of the Bs0 → μ+ μ- branching fraction already in 2010 and that approximately 3fb-1 at √s = 14TeV are enough for a 3σ evidence of a SM signal. In a particle physics experiment, the precise measurement of the charged particle trajectories is essential. Indeed tracking gives experimental access to their momentum and allows the reconstruction of the physical properties of the short-lived particle of which they are the decay products. The Inner Tracker is the detector that provides tracking information for the particles ying in the innermost part of LHCb. Because of its central position, the Inner Tracker calls for the use of very light-weighted material which compete with the precision and rigidity required by such a detector. During my thesis work, I contributed to the construction of the Inner Tracker through the set up of an assembly procedure for the detector boxes, uncovering several design aws and contributed to solve them pragmatically. I defined quality requirements at key steps of the assembly and implemented tests to assess them. I conducted the assembly of the twelve Inner Tracker detectors boxes that were installed in the LHCb cavern in Summer 2008. After software alignment, the overall precision of the Inner Tracker modules position is on average 19 µm along the relevant direction. The careful box assembly and the quality tests along the procedure allowed to keep the dead strips fraction below 1 %. Finally, tracks from the LHC collisions have been seen

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15538. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate

Les droits disciplinaires des fonctions publiques : « unification », « harmonisation » ou « distanciation ». A propos de la loi du 26 avril 2016 relative à la déontologie et aux droits et obligations des fonctionnaires

The production of tt‾ , W+bb‾ and W+cc‾ is studied in the forward region of proton–proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98±0.02 fb−1 . The W bosons are reconstructed in the decays W→ℓν , where ℓ denotes muon or electron, while the b and c quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions.The production of $t\overline{t}$, $W+b\overline{b}$ and $W+c\overline{c}$ is studied in the forward region of proton-proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98 $\pm$ 0.02 \mbox{fb}^{-1}. The $W$ bosons are reconstructed in the decays $W\rightarrow\ell\nu$, where $\ell$ denotes muon or electron, while the $b$ and $c$ quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions

Physics case for an LHCb Upgrade II - Opportunities in flavour physics, and beyond, in the HL-LHC era

The LHCb Upgrade II will fully exploit the flavour-physics opportunities of the HL-LHC, and study additional physics topics that take advantage of the forward acceptance of the LHCb spectrometer. The LHCb Upgrade I will begin operation in 2020. Consolidation will occur, and modest enhancements of the Upgrade I detector will be installed, in Long Shutdown 3 of the LHC (2025) and these are discussed here. The main Upgrade II detector will be installed in long shutdown 4 of the LHC (2030) and will build on the strengths of the current LHCb experiment and the Upgrade I. It will operate at a luminosity up to 2×1034 cm−2s−1, ten times that of the Upgrade I detector. New detector components will improve the intrinsic performance of the experiment in certain key areas. An Expression Of Interest proposing Upgrade II was submitted in February 2017. The physics case for the Upgrade II is presented here in more depth. CP-violating phases will be measured with precisions unattainable at any other envisaged facility. The experiment will probe b → sl+l−and b → dl+l− transitions in both muon and electron decays in modes not accessible at Upgrade I. Minimal flavour violation will be tested with a precision measurement of the ratio of B(B0 → μ+μ−)/B(Bs → μ+μ−). Probing charm CP violation at the 10−5 level may result in its long sought discovery. Major advances in hadron spectroscopy will be possible, which will be powerful probes of low energy QCD. Upgrade II potentially will have the highest sensitivity of all the LHC experiments on the Higgs to charm-quark couplings. Generically, the new physics mass scale probed, for fixed couplings, will almost double compared with the pre-HL-LHC era; this extended reach for flavour physics is similar to that which would be achieved by the HE-LHC proposal for the energy frontier

LHCb upgrade software and computing : technical design report

This document reports the Research and Development activities that are carried out in the software and computing domains in view of the upgrade of the LHCb experiment. The implementation of a full software trigger implies major changes in the core software framework, in the event data model, and in the reconstruction algorithms. The increase of the data volumes for both real and simulated datasets requires a corresponding scaling of the distributed computing infrastructure. An implementation plan in both domains is presented, together with a risk assessment analysis

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15538. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

peer reviewedThe Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate